BIOPHARMACEUTICAL IMPURITY ISSUES
This article was originally published in The Gold Sheet
...are drawing attention in the search for a more coherent regulatory approach to the complexities involved. With significant implications for the development and clearance of both new and follow-on biotech products, FDA and industry are evaluating their experience to date to find where meaningful impurity standards and best practices may lie. At a recent “CMC strategy forum,” participants discussed the challenges of assessing and controlling the variety of process- and product-related impurities involved in developing biopharmaceuticals. [Included are presentations at the forum by FDA regulatory officials on: process-related impurities, host cell proteins, product-related impurities, and aggregates.]
You may also be interested in...
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.